Major studies addressing various aspects of the treatment of deep vein thrombosis are reviewed. It has lately been demonstrated that heparin should be dosed according to body weight and is preferably given as subcutaneous injections twice daily. Alternatively, low-molecular-weight heparins may be given in a fixed dose once daily, which does not require monitoring. Oral anticoagulation should be started concomitantly with heparin and targeted at an international normalized ratio of 2.0-3.0. This treatment should continue for a longer duration than previously accepted, in many cases for 6 months. For patients with contraindications to oral anticoagulation, secondary prophylaxis with a low-molecular-weight heparin is also effective and safe.
INTRODUCTION
Heparin has been used as the initial anticoagulant for the treatment of venous thrombosis since its preventive effect was demonstrated independently by Crafoord 1 and Murray et a]. 2 in 1937. The first oral anticoagulant, the vitamin K antagonist dicoumarol, was introduced into clinicalpractice by Lehmann! and Allen et 01. 4 in 1942, and these two therapeutic principles have thereafter remained the basis for treatment of venous thrombosis. Questions regarding the details of therapy were, however, left unanswered for many years, resulting in a great variability in clinicalpractice. A number of randomized studies over the past decades have contributed to the establishment of a more standardized and scientifically based regimen for the treatment of venous thrombosis. The major outcomes of the randomized studies cited here are presented in Table 1 . Although this review does not deal specifically with the treatment of pulmonary embolism, this condition is generally perceived as the same disease as deep vein thrombosis, and the anticoagulant treatment should therefore not differ.
THE NECESSITY TO TREAT
The first randomized study in this field, published by Barritt and Jordan in 1960 5 , demonstrated the necessity of anticoagulation in pulmonary embolism. In the untreated group there was a recurrence rate of 53%, five of which were fatal, compared to no recurrences among those who received heparin, and the study was therefore interrupted prematurely. Starting with an oral anticoagulant alone is not sufficient, because of the delay of 3-5 days until this treatment becomes effective. This was proven by Brandjes et 
in a study of patients with proximal deep vein thrombosis
Correspondence to: Dr Sam SChulman, Department of Intemal Medicine, Karolinska Hospital, S-171 76 Stockholm, Sweden (DVT), where an excess of symptomatic recurrences in the group receiving oral anticoagulation alone led to early termination of the trial", The difference in asymptomatic progressions of the thrombi was even more striking (39.6 versus 8.2% in the non-heparinized and heparinized groups, respectively). Until the publication of this study in 1992, the routine in the Netherlands had been to treat patients with DVT outside the hospital with a fast-acting oral anticoagulant alone.
Sawyer et 01. suggested in 1964 that treatment of thrombi confined to the calf veins would not be necessary in active patients 7 . The strategy of following patients with distal DVT outside the hospital and only to treat when serial impedance plethysmography gave evidence of progression to the proximal veins has been utilized in Canada and the Netherlands'S", but this routine is cumbersome and has not gained popularity. Furthermore, although the risk of pulmonary embolism is smaller the more distally the thrombus is locatedl'', the incidence may not be negligible in calf vein thrombosis11.
MONITORING AND DOSING OF HEPARIN
The treatment with heparin is initiated with a bolus dose intravenously to achieve rapid prolongation of the activated partial thromboplastin time (APTT). The rationale for exceeding a certain therapeutic threshold is based on several studies. Basuet 01. found in a prospective study of 234 patients that patients with recurrent events during treatment with heparin had a significantly lower mean APTT than the othersl '. None of the patients with a mean APTT between 1.5 and 2.5 times the control experienced recurrences 1 2. In a study comparing continuous intravenous infusion with subcutaneous injections of heparin the latter group had a higher incidence of recurrent events, which essentially Although the importance of exceeding a threshold APTI to achieve efficacy was demonstrated in three studies12-14, there was no clear evidence that further prolongation of the APTT above an upper limit (usually 2.5 times control) resulted in an increased incidence of haemorrhage. In a study where patients with proximal DVT, treated with continuous infusion of heparin, were randomized between initiation of oral anticoagulation immediately or after five days, 69% and 24%, respectively, had APTT responses above 2.5 times the mean normal control'".
Haemorrhagic complications occurred in 8/93 patients (8.6%) with supratherapeutic responsesand in 131106(12.3%) without supratherapeutic responses. Thus no association seems to exist between excessive APTI prolongations and bleeding. Relative heparin resistance is a common problem, and about one-third of all patients require more than 35 000 unitsl 24 h16. In a randomized trial in 131 resistant patients, monitoring by anti-factor Xa levels, targeted to O. 35-0.67 UI mL, was more sensitive than monitoring by APTTI6. As a result, with the heparin assaySignificantly lower infusion doses were required (about 4000 units less per day) and only one minor bleeding episode (1.5%) occurred versus one major and three minor bleeding episodes (6.1 %) in the APTT group (not statistically significant though) with no difference in recurrent thromboembolism. By use of the heparin assay, unnecessary dose-escalation of heparin seems to be avoided.
ROUTE OF HEPARIN ADMINISTRATION
A major issue regarding treatment with heparin has been the optimal mode of administration. Intermittent intravenous injections appear to be less safe than continuous infusion17, but most of the studies have compared continuous infusion with subcutaneous injections. In a meta-analysis of six studies with strong methodology, subcutaneous injections twice daily came out favourably with fewer recurrences or extensions of thrombi (relative risk 0.62) and a trend to fewer haemorrhages (relative risk 0.79)18. Addition to the analysis of two more studies with less strict methodology did not change the results. Administration of heparin by the subcutaneous route facilitates early mobilization of the patient and allows for rapid transition to an outpatient or home setting.
THE ROLE OF LOW-MOLECULAR-WEIGHT HEPARINS
These possibilities have been brought to the centre of attention by the introduction of low-molecular-weight heparins (LMWHs) in the therapy of established thrombosis. Because of their greater bioavailability at low doses subcutaneously and longer half-life than standard heparins, LMWHs have a sufficient effect when injected only once daily!", More than 15 studies have compared LMWHs with continuous infusion of adjusted-dose standard heparin in the initial treatment of venous thromoembolism. Five of the randomized studies had in common the outcome measure of recurrent venous thromboembolism during follow-up. A meta-analysis of these studies revealed that LMWHs, injected subcutaneously in a fixed dose once or twice daily, offered significant advantages regarding recurrence rate, haemorrhage and mortalitv-". There were, however, several differences between the individual studies regarding type of LMWH, dosage, monitoring of the effect of heparin and initial extent of the thrombi, and most of the difference in haemorrhagic complications was contributed by just one of the studies.
When only one type of LMWH was evaluated in another meta-analysis of three studies with almost identical design, no advantages in relation to standard heparin emerged 21 . Whether this indicates a difference in the effects of the various LMWHs or that the results of the first meta-analysis were due to pure chance is still not clear.
With the evidence at hand that LMWHs injected subcutaneously are at least as efficient and safe as standard heparin, and that there is no need for or benefit of monitoring by anti-Xa levels when weight-adjusted doses of LMWH are given, the road has been opened for immediate or very early discharge of the patient from hospital. Preliminary data are now emerging from several trials that outpatient treatment with LMWHs is as safe as in-hospital treatment with standard heparin during the initial phase.
Patients presenting with submassive pulmonary embolism with or without concomitant symptoms ofDVT also seem to do well on LMWHs. The first study compared infusion of standard heparin with three different doses of Fraxiparine subcutaneouslv-s. When the latter was given in doses of 600 or 900 anti-Xa U/kg, divided in three daily injections, there was a higher rate of complications. With 400 U/kg as two doses, results similar to those with continuous infusion of standard heparin were obtained, but there was no long-term follow-up and the number of patients was small. Preliminary data from a trial with Fragmin 120 anti-Xa U/kg twice daily also demonstrate that this is an alternative to standard intravenous heparin in these patients 23 . 
THE ,NECESSITY OF SECONDARY PROPHYLAXIS
The need for continued anticoagulation beyond the initial phase was indicated in a retrospective study by Coon and Willis in 1973 24 . This was corroborated by a randomized study in patients with proximal DVT, where the group receiving low-dose heparin, 5000 units every 12 h, had significantly more recurrences than those treated with full-dose warfarin 25 . It has been suggested that the patients treated with low-dose heparin were at a disadvantage for recurrence because the level of antithrombin III, depressed by the initial full-dose heparin, did not have the same chance to recover as in the warfarin group26. It would, however, be unethical to compare an agent with placebo in secondary prophylaxis after proximal DVT. This became even more evident when a randomized study, comparing warfarin and compression stockings with stockings alone in distal DVT, showed significantly more recurrences in the non-anticoagulated group27.
ALTERNATIVES FOR SECONDARY PROPHYLAXIS
The best therapeutic choice for the secondary prophylaxis has been the subject of several trials. When heparin in subcutaneous injections is adjusted to keep the mid-interval APTT at 1.5 times control, there is no difference in the rate of recurrence compared to warfarin (aimed at international normalized ratio (3.0-4.5)28. The risk of haemorrhage was greater with warfarin, but this high intensity of oral anticoagulation has mainly been applied in North America, where less sensitive thromboplastin reagents were used. When this intensity was compared with a lower intensity, corresponding to INR 2.0-2.5, which was used in many European countries, the latter regimen proved to be both effective and safe 29.
LMWHs have also been evaluated for secondary prophylaxis after venous thrombosis. In a comparison of Enoxaparin 40 mg (4000 anti-Xa U) once daily and warfarin targeted at an INR of 2.0-3.5, there was no difference in clinical recurrences over three months-". The risk of complications was, on the other hand, greater with warfarin for all types of haemorrhage, though not for major haernorrhages-", Another study selected patients considered to have contraindications to oral anticoagulant therapy for long-term prophylaxis with Fragmin 5000 anti-Xa U twice daily or standard heparin 10000 units twice dail y31. There were no differences in rates of recurrence or haemorrhage, but symptomatic vertebral fractures occurred in 6/40 on standard heparin and 1140 on Fragmin, or in 5/12 and 0/12 patients, respectively, aged 80 years or more. The latter difference was statistically significant and should serve as a warning against long-term standard heparin for this purpose.
INITIATION OF ORAL ANTICOAGULATION
Assuming that oral anticoagulant therapy is selected for long-term prophylaxis, the time point for initiation of this treatment should be the start of heparinization. This routine has been employed for several decades in many European countries, and the average number of days on heparin is about five. Some patients take considerably longer to reach the therapeutic range, corresponding to INR 2-3. Until then discontinuation of heparin is not permissi~le.
The risk of heparin induced thrombocytopenia, which usually has its onset after 5-12 days of heparinization, may be increased in that situation. In a randomized study comparing a regular and a more intensive initiation of oral anticoagulation with warfarin (15, 7.5, 7.5 mg versus 15 mg daily) in patients with DVT, the latter regimen led to an average induction period of 4 days (and heparinization for a total of 5 days)32. This was mainly the result of a reduced induction time in patients requiring high maintenance doses, and the risk of clinical progression was very low in both groups.
In an Australian study warfarin was started within 3 days (usually on day 1) or after 7 days of heparinization of patients with DVT or pulmonary embolism, and the duration of treatment with heparin was 4.1 and 9.5 days, respectively, with no difference in recurrent episodesl '.
In North America oral anticoagulation has customarily been initiated after 5 days, resulting in durations of heparinization of 10-14 days. The duration of hospitalization, the time until mobilization of the patient and most likely also the risk of heparin induced thrombocytopenia are increased. This has probably changed after a Canadian study which verified that no differences in the rates of haemorrhages or rethrombosis are seen between regimens with initiation of oral anticoagulation on the first or on the fifth day!5.
DURATION OF ORAL ANTICOAGULATION
The optimal duration of oral anticoagulation was initially investigated in several smaller randomized studies, which gave the impression that it could be as short as 4-6 weeks after the first episode of venous thromboembolism without any increase in the rate of recurrence, but this concept recently required revision 34 • 35. The study of the Research Committee of the British Thoracic Society demonstrated fewer recurrences with 3 months of oral anticoagulation than with 4 weeks-". Objective diagnosis was, however, not obtained initially in all patients and was obtained in less than half of the recurrent events. In our own trial, which is the largest so far, the group with 6 months of oral anticoagulation had fewer recurrences than that with 6 weeks, and the difference was of the same magnitude in almost all subgroups35 . The difference in the rate of recurrence was determined by a high incidence in the 6 week-group from the time of cessation until 6 months. Thereafter both groups had an identical, linear accumulation of recurrences corresponding to 5-6% annually up to 2 years after the initial thromboembolic event (Figure 1 ). We now have preliminary data from 4 years of follow-up, and this linear increase continues unabated, but the difference between the groups is maintained. Our conclusion is that 6 months of oral anticoagulation is required in most cases after the first thromboembolic event. A further prolongation of the secondary prophylaxis should be based on risk factors as well as the attitude and compliance of the patient, including the problems encountered during the first 6 months. The role of low-dose or minidose warfarin should be evaluated in this setting. A recent study demonstrated that normalization of venous flow, as measured by impedance plethysmography after 4 weeks, is not a good predictor of future recurrences 36.
For patients with a second thromboembolic event little is known about the optimal duration, but a randomized study of over 200 patients, followed by us for 4 years, is near conclusion and should yield some useful data. After the third episode most physicians favour long-term anticoagulation. In case of a major event, even if it is the first, for example pulmonary embolism or iliac vein thrombosis, in combination with the diagnosis of a hereditary thrombogenic abnormality (deficiency of antithrombin, protein C or S or activated protein C resistance) life-long anticoagulation is usually considered necessary. There are strong recommendations for prolonged and intensified oral anticoagulation after venous thromboembolism in patients with a lupus anticoagulant or antiphospholipid antibodies, but these are based on data from retrospective studies, which may have been biased 37 , 38. The presence of a hypofibrinolytic state, as indicated by an elevated plasminogen activator inhibitor or a reduced release of the tissue type plasminogen activator, does not seem to warrant long-term anticoagulation". In a retrospective comparison of two oral anticoagulants, warfarin therapy was more stable and required fewer prothrombin time assays than acenocoumarolt".
CESSATION OF ORAL ANTICOAGULATION
Abrupt withdrawal of anticoagulation is connected with an elevation of prothrombin fragment 1+2 and thrombinantithrombin complex, indicating activation of coagulation 41 . This may be of importance if the duration oftreatment is short and there is still thrombogenic activity in the vessel wall. What happened to the 454 patients in our trial who were treated with warfarin for 6 months followed by an abrupt discontinuationt-? This group had seven recurrences during the following month and thereafter an average of two per month. With an equal-sized group also randomized to 6 months but with gradual cessation and only two recurrences even in the first month after treatment, the difference would not have achieved statistical significance.
ANTICOAGULANT THERAPY IN PREGNANCY
The hazards of warfarin embryopathy are well knownf". Heparin does not cross the placenta and is therefore routinely used throughout pregnancy in patients with venous thromboembolism. For acute events during pregnancy fulldose heparin is given as a continuous intravenous infusion for 5-7 days or until acute symptoms have subsided, usually followed by the same dose subcutaneously, divided in two daily doses for a total of 1 month. Secondary prophylaxis until the end of pregnancy is generally given with standard heparin subcutaneously at a dose of about 5000-10000 units every 12 h. Monitoring can be performed with APTT or heparin level, from samples taken 2-4 h post-injection. The APTT should be 1.5 times normal or prolonged by 5-10 s and the heparin level 0.05-0. 15 anti-Xa IUI mL. In patients at high risk, for example with a hereditary thrombogenic coagulopathy, these results should be aimed for at the trough level, immediately before the next dose. By monitoring with heparin levels, slightly lower doses of heparin will be used without any loss in efficacy43. LMWHs are increasingly being used in pregnancy, especially in women with allergic reactions to standard heparin. In patients with previous therapeutic failures on prophylaxis with heparin, for example with lupus anticoagulants, there is a possibility to switch to warfarin during the second timester, since there are some favourable data on this regimen in pregnant women with cardiac prosthcses'l".
CONCLUSIONS
Thisreview has not dealt with thrombolytic therapy, the role of which is debatable in most types of venous thrombosis. In massive pulmonary embolism thrombolysis should be considered. Before one embarks on thrombolytic therapy the risk of major haemorrhage must be taken into account, and a decision analysis has demonstrated that if patient preferences are also regarded, the benefits of thrombolysis will be outweighed by potential risks 45 . If newer thrombolytic agents cause less haemorrhage, future trials should include comparisons with LMWHs, which are now entering the first line of therapy for acute venous thromboembolism and combine a high degree of safety and efficacy wit]. simplicity. Thanks to these advantages of LMWHs venous thrombosis is now increasingly being treated outside the hospital. The traditional inpatient investigations of a potential underlying disease and of thrombogenic biochemical abnormalities must under these circumstances not be omitted, and firm routines for the total management of patients with venous thromboembolism need to be established. New data favour a longer duration of oral anticoagulation than was previously believed optimal. The decision is complex, being based on cost-benefit as well as a multitude of risk factors, and studies weighing the importance of these different aspects are to be expected.
